This study explores two novel on-demand drug treatments for women with Hypoactive Sexual Desire Disorder (HSDD) or Female Sexual Interest/Arousal Disorder (FSIAD), conditions characterized by low sexual desire that impact quality of life. The first treatment combines testosterone with a phosphodiesterase type 5 (PDE5) inhibitor to enhance sexual cue sensitivity,
This narrative review explores the neurobiological mechanisms underlying hypoactive sexual desire disorder (HSDD) in women, focusing on the inhibitory role of serotonin in sexual desire. The review highlights that serotonin overactivity may contribute to HSDD by suppressing excitatory pathways involved in sexual function. It discusses pharmacologic treatments targeting serotonin, particularly
The article “Which Postmenopausal Women Should Use Testosterone for Low Sexual Desire?” published in JAMA (2020) examines the criteria for prescribing testosterone therapy to postmenopausal women experiencing hypoactive sexual desire disorder (HSDD). It discusses the efficacy and safety of testosterone treatment, emphasizing the need for accurate diagnosis and individualized patient
A meta-analysis published in The Journal of Sexual Medicine reviewed data from two Phase III trials (INTIMATE SM 1 and 2) assessing the efficacy and safety of transdermal testosterone therapy in surgically postmenopausal women with hypoactive sexual desire disorder (HSDD) undergoing estrogen therapy. Women receiving testosterone experienced significant improvements in
This cross-sectional study examined the prevalence of low sexual desire and hypoactive sexual desire disorder (HSDD) in 2,207 U.S. women aged 30 to 70 years in stable relationships. Findings showed that low sexual desire was reported by 26.7% of premenopausal women, 52.4% of naturally menopausal women, and 43.6% of surgically
This 2020 article provides a comprehensive overview of hypoactive sexual desire disorder (HSDD) in women, a condition characterized by a persistent lack of sexual desire that causes personal distress or interpersonal difficulties and is not due to another medical condition or medication. The study explores the multifaceted etiology of HSDD,
Flibanserin is a mixed 5-HT1A agonist and 5-HT2A antagonist approved for treating premenopausal women with hypoactive sexual desire disorder (HSDD). It is the first FDA-approved medication for this condition, showing efficacy by increasing the number of satisfying sexual events. However, flibanserin has been associated with side effects, including hypotension and
This observational study surveyed 2,467 European women aged 20-70 years to assess the prevalence of hypoactive sexual desire disorder (HSDD) among premenopausal, naturally menopausal, and surgically menopausal women. The analysis focused on 1,356 women with sexual partners, revealing that surgically menopausal women were significantly more likely to experience low sexual
The study titled Hypoactive Sexual Desire Disorder in Postmenopausal Women explores the impact of declining sex hormone levels, particularly estrogens and androgens, on sexual desire in postmenopausal women. It highlights that while conventional hormone therapy (estrogens or estrogens with progestogens) can relieve vaginal atrophy and dyspareunia, it does not consistently
The study titled Hypoactive Sexual Desire Disorder in Postmenopausal Women: US Results from the Women’s International Study of Health and Sexuality (WISHeS), published in Menopause in 2006 (PMID: 16607098), examines the prevalence and impact of hypoactive sexual desire disorder (HSDD) in postmenopausal women in the United States. The research found
